SCHEMBL6714247

SCHEMBL6714247

COC(=O)c1ccc(NC(=S)N[C@@H](C(=O)Nc2ccccc2C)C(C)C)cc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.62
NPC1 O15118 3/20 0.62
RAB9A P51151 3/20 0.62
SMN1; SMN2 Q16637 5/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
POLB P06746 1/20 0.54
STAT3 P40763 1/20 0.54
ALOX12 P18054 1/20 0.54
GAA P10253 4/20 0.50
LMNA P02545 3/20 0.50
HPGD P15428 2/20 0.50
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 2/20 0.48
HTT P42858 2/20 0.47
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6716813 1.00 MAPT (0.62) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL8346734 1.00 MAPT (0.62) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL8345109 0.87 MAPT (0.62) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6715869 0.84 MAPT (0.59) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6713910 0.83 MAPT (0.61) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6714044 0.83 MAPT (0.61) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6717225 0.81 MAPT (0.58) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6713855 0.79 MAPT (0.56) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6723389 0.79 MAPT (0.56) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6717221 0.75 MAPT (0.62) MAPTNPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 MAPT 427/4885NPC1 120/4885RAB9A 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.